Authors: Chodak, GW Kolvenbag, GJCM

Citation: Gw. Chodak et Gjcm. Kolvenbag, Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer?, PROSTATE C, 4(2), 2001, pp. 72-80

Authors: Myers, RE Hyslop, T Jennings-Dozier, K Wolf, TA Burgh, DY Diehl, JA Lerman, C Chodak, GW

Citation: Re. Myers et al., Intention to be tested for prostate cancer risk among African-American men, CANC EPID B, 9(12), 2000, pp. 1323-1328

Authors: Kirsh, EJ Worwag, EM Sinner, M Chodak, GW

Citation: Ej. Kirsh et al., Using outcome data and patient satisfaction surveys to develop policies regarding minimum length of hospitalization after radical prostatectomy, UROLOGY, 56(1), 2000, pp. 101-106

Authors: Sarosdy, MF Schellhammer, PF Soloway, MS Vogelzang, NJ Crawford, ED Presti, J Chodak, GW Mitchell, P Porter, L

Citation: Mf. Sarosdy et al., Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer, BJU INT, 83(7), 1999, pp. 801-806

Authors: List, MA Sinner, M Chodak, GW

Citation: Ma. List et al., Improving knowledge about prostate cancer: the development of an educational program for African-Americans, PROSTATE C, 2(4), 1999, pp. 186-190

Authors: Myers, RE Chodak, GW Wolf, TA Burgh, DY McGrory, GT Marcus, SM Diehl, JA Williams, M

Citation: Re. Myers et al., Adherence by African American men to prostate cancer education and early detection, CANCER, 86(1), 1999, pp. 88-104